Overview

A Unique Regimen for Treatment of Helicobacter Pylori Infection

Status:
Recruiting

Trial end date:
2023-04-01

Target enrollment:
0

Participant gender:
All

Summary

The triple treatment including Proton pump inhibitor (PPI) -clarithromycin and amoxicillin or metronidazole was proposed 30 years ago at the first Maastricht conference to treat helicobacter pylori (H. pylori) infection and since that time, it has become the universal and standard treatment for helicobacter pylori. However, the efficacy of this triple regimen has been seriously challenged, and they are gradually becoming ineffective

Phase:

Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Sherief Abd-Elsalam

Treatments:

Omeprazole

Criteria

Inclusion Criteria:

- Patients aged older than 21 years Presenting by Dyspepsia Infected by H. pylori (as
proved by positive stool antigen test) Agreed to participate in the study and signed
the consent

Exclusion Criteria:

- Patients who have received treatment with proton pump inhibitors within 2 weeks, NSAID
or antibiotics within 4 weeks before study entry Patients who had received H pylori
treatment before. Patients presenting by upper gastrointestinal bleeding Pregnant
females Patients who have significant gastrointestinal, renal, hepatic,
cardiovascular, metabolic, hematological disease.